Market revenue in 2023 | USD 13,081.0 million |
Market revenue in 2030 | USD 18,188.7 million |
Growth rate | 4.8% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.73% in 2023. Horizon Databook has segmented the North America rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The North America rheumatoid arthritis therapeutics market continues to grow and evolve, driven by demographic shifts, advancements in medical research, regulatory changes, and an increasing emphasis on personalized healthcare.
The aging population across North America significantly impacts the demand for Rheumatoid Arthritis (RA) therapeutics. As people live longer, the prevalence of chronic conditions such as RA increases, boosting the need for effective treatment options. This demographic trend is a primary driver of sustained market growth.
Medical research and innovation in RA therapeutics are notably advancing, with significant investments in developing new drugs and treatment modalities. Biologic drugs and biosimilars have become increasingly popular due to their effectiveness in managing the symptoms and progression of RA.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America rheumatoid arthritis therapeutics market, including forecasts for subscribers. This continent databook contains high-level insights into North America rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account